Search
vismodegib (Erivedge)
Indications:
- basal cell carcinoma
- locally advanced or metastasized
- surgery or radiation is not an option
Contraindications:
- pregnancy
Pregnancy category: X
Dosage:
- PO QD
Adverse effects:
- muscle spasms
- alopecia
- weight loss
- nausea/vomiting
- diarrhea, constipation
- anorexia
- dysgeusia
- fatigue
Mechanism of action:
- inhibits Hedgehog pathway
Notes:
- maintenane4 of remission in those with complete response after cessation of drug
- marketed by Genentech
Related
sonidegib (Odomzo)
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=24776445
References
- FDA NEWS RELEASE: Jan. 30, 2012
FDA approves new treatment for most common type of skin cancer
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm
- Herms F, Lambet J, Grob JJ et al
Follow-Up of Patients With Complete Remission of Locally Advanced
Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter
French Study of 116 Patients.
J Clin Oncol. 2019 Dec 1;37(34):3275-3282
PMID: 31609670
https://ascopubs.org/doi/abs/10.1200/JCO.18.00794?journalCode=jco